Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Lunai Bioworks Inc. issued an aggregate of 1,433,621 additional shares of common stock of warrant to three of the Company's holders of secured promissory notes for part of the debt exchange.
- Security
- warrant
- Shares
- an aggregate of 1,433,621 additional shares of common stock
- Purchaser
- three of the Company's holders of secured promissory notes
- Consideration
- part of the debt exchange
Exact text from the filing
common stock purchase warrants to acquire an aggregate of 1,433,621 additional shares of common stock (the “Warrants”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Lunai Bioworks Inc. issued an aggregate of 3,909,293 shares of common stock to three of the Company's holders of secured promissory notes for cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest.
- Security
- common stock
- Shares
- an aggregate of 3,909,293 shares
- Purchaser
- three of the Company's holders of secured promissory notes
- Consideration
- cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest
Exact text from the filing
Pursuant to the Debt Exchange Agreements, the Holders agreed to cancel and extinguish an aggregate of $828,770.14 of outstanding principal and accrued interest owed under the Investor Notes in exchange for an aggregate of 3,909,293 shares of the Company’s common stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lunai Bioworks Inc. entered into Debt Exchange Agreements with three of the Company’s holders of secured promissory notes valued at $828,770.14 (effective 2026-03-24).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- three of the Company’s holders of secured promissory notes
- Value
- $828,770.14
- Effective
- 2026-03-24
Exact text from the filing
On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lunai Bioworks Inc. entered into Acquisition Agreement with Clemann Group, SAS valued at $20.0 million (effective 2026-03-26).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Clemann Group, SAS
- Value
- $20.0 million
- Effective
- 2026-03-26
Exact text from the filing
On March 26, 2026, the Company entered into a binding agreement (the “Acquisition Agreement”) with Clemann Group, SAS, or its assignee (the “Seller”), pursuant to which the Company agreed to acquire certain blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets (the “Transaction”).
View on SEC.gov